Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.gov_Identifier |
NCT01358877
|
| gptkbp:controlArm |
placebo + trastuzumab + chemotherapy
|
| gptkbp:designer |
double-blind
placebo-controlled randomized |
| gptkbp:endPoint |
invasive disease-free survival
|
| gptkbp:enrollment |
4805
|
| gptkbp:focusesOn |
gptkb:HER2-positive_breast_cancer
|
| gptkbp:foundIn |
pertuzumab improved invasive disease-free survival
|
| https://www.w3.org/2000/01/rdf-schema#label |
APHINITY trial
|
| gptkbp:period |
Phase III
|
| gptkbp:population |
early-stage breast cancer patients
|
| gptkbp:primaryPublicationYear |
2017
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:sponsor |
F. Hoffmann-La Roche Ltd
|
| gptkbp:startYear |
2011
|
| gptkbp:studies |
gptkb:pertuzumab
gptkb:trastuzumab |
| gptkbp:treatmentArm |
pertuzumab + trastuzumab + chemotherapy
|
| gptkbp:分布地区 |
international
|
| gptkbp:bfsParent |
gptkb:Breast_International_Group
|
| gptkbp:bfsLayer |
5
|